Cellular senescence in cancer treatment: friend or foe?
AUTOR(ES)
Kahlem, Pascal
FONTE
American Society for Clinical Investigation
RESUMO
Damage to DNA, the prime target of anticancer therapy, triggers programmed cellular responses. In addition to apoptosis, therapy-mediated premature senescence has been identified as another drug-responsive program that impacts the outcome of cancer therapy. Here, we discuss whether induction of senescence is a beneficial or, rather, a detrimental consequence of the therapeutic intervention.
